Medibio Limited
Medibio Limited (MDBIF) Financial Performance & Income Statement Overview
Explore the financials of Medibio Limited (MDBIF), including yearly and quarterly data on income, cash flow, and balance sheets.
Medibio Limited (MDBIF) Income Statement & Financial Overview
View the income breakdown for Medibio Limited MDBIF across both annual and quarterly reports.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $9566.00 | $293.00 | $147.00 |
| Cost of Revenue | $46352.00 | $46781.00 | $1.00 | $1.00 |
| Gross Profit | -$46352.00 | -$37215.00 | $292.00 | $146.00 |
| Gross Profit Ratio | $0.00 | -$3.89 | $1.00 | $0.99 |
| R&D Expenses | $11263.00 | $3011.00 | $90221.00 | $45111.00 |
| SG&A Expenses | $966320.00 | $1.04M | $964038.00 | $157125.00 |
| Operating Expenses | $977583.00 | $1.03M | $1.05M | $1.33M |
| Total Costs & Expenses | $1.02M | $1.07M | $1.33M | $1.33M |
| Interest Income | $0.00 | $2260.00 | $0.00 | $3308.00 |
| Interest Expense | $0.00 | $13873.00 | $3312.00 | $0.00 |
| Depreciation & Amortization | $46352.00 | $46781.00 | $274463.00 | $248116.00 |
| EBITDA | -$977590.00 | -$1.03M | -$416098.00 | -$416098.00 |
| EBITDA Ratio | $0.00 | -$107.37 | -$3597.17 | -$2830.60 |
| Operating Income | -$1.02M | -$1.07M | -$1.33M | -$664214.00 |
| Operating Income Ratio | $0.00 | -$112.26 | -$4533.89 | -$4518.46 |
| Other Income/Expenses (Net) | $872350.00 | -$11613.00 | -$1.32M | -$660709.00 |
| Income Before Tax | -$151590.00 | -$1.09M | -$2.65M | -$1.32M |
| Income Before Tax Ratio | $0.00 | -$113.48 | -$9043.84 | -$9013.08 |
| Income Tax Expense | -$2.00 | $0.00 | -$3.00 | $0.00 |
| Net Income | -$151590.00 | -$1.09M | -$2.65M | -$1.32M |
| Net Income Ratio | $0.00 | -$113.48 | -$9043.84 | -$9013.08 |
| EPS | -$0.001 | -$0.004 | -$0.01 | -$0.007 |
| Diluted EPS | -$0.001 | -$0.004 | -$0.01 | -$0.007 |
| Weighted Avg Shares Outstanding | $309.27M | $306.29M | $181.24M | $181.72M |
| Weighted Avg Shares Outstanding (Diluted) | $309.27M | $306.29M | $181.24M | $197.58M |
Over the past four quarters, Medibio Limited demonstrated steady revenue growth, increasing from $147.00 in Q3 2023 to $0.00 in Q4 2024. Operating income reached -$1.02M in Q4 2024, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$977590.00, reflecting operational efficiency. Net income rose to -$151590.00, with EPS at -$0.001. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan